Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca 2+ responses and chemotaxis in cultured human vascular smooth muscle cells

British Journal of Pharmacology

Volumn 145, Issue 6, 2005, Pages 811-817

  Patel, Mahendra K ^a   Clunn, Gerard F ^a   Lymn, Joanne S ^a   Austin, Oneka ^a   Hughes, Alun D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotaxis; Intracellular calcium; L type calcium channels; Vascular smooth muscle cells

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ALPHA SMOOTH MUSCLE ACTIN; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; DIHYDROPYRIDINE DERIVATIVE; FURA 2; GELATIN; PLATELET DERIVED GROWTH FACTOR BB; POTASSIUM CHLORIDE; VERAPAMIL;

ARTICLE; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG BINDING SITE; FETAL CALF SERUM; FLUOROMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SAPHENOUS VEIN; VASCULAR SMOOTH MUSCLE;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ACTINS; AMLODIPINE; CALCIUM; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CELLS, CULTURED; CHEMOTAXIS; CULTURE MEDIA, SERUM-FREE; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET-DERIVED GROWTH FACTOR; SAPHENOUS VEIN; VERAPAMIL;

EID: 23044470352     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706237     Document Type: Article

References (37)

1. AIBA, S. & CREAZZO, T.L. (1993). Comparison of the number of dihydropyridine receptors with the number of functional L-type calcium channels in embryonic heart. Circ. Res., 72, 396-402.
2. BILATO, C., CURTO, K.A., MONTICONE, R.E., PAULY, R.R., WHITE, A.J. & CROW, M.T. (1997). The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/ calmodulin-dependent protein kinase II. J. Clin. Invest., 100, 693-704.
3. BORHANI, N.O., MERCURI, M., BORHANI, P.A., BUCKALEW, V.M., CANOSSA-TERRIS, M., CARR, A.A., KAPPAGODA, T., ROCCO, M.V., SCHNAPER, H.W., SOWERS, J.R. & BOND, M.G. (1996). Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA, 276, 785-791.
4. CAMPBELL, G.R. & CHAMLEY-CAMPBELL, J.H. (1981). Smooth muscle phenotypic modulation: role in atherogenesis. Med. Hypotheses, 7, 729-735.
5. CHAMLEY-CAMPBELL, J., CAMPBELL, G.R. & ROSS, R. (1979). The smooth muscle cell in culture. Physiol. Rev., 59, 1-61.
6. CHAMLEY-CAMPBELL, J.H. & CAMPBELL, G.R. (1981). What controls smooth muscle phenotype? Atherosclerosis, 40, 347-357.
7. CHAN, P., MUNRO, E., PATEL, M., BETTERIDGE, L., SCHACHTER, M., SEVER, P. & WOLFE, J. (1993). Cellular biology of human intimal hyperplastic stenosis. Eur. J. Vasc. Surg., 7, 129-135.
8. CLUNN, G.F., LYMN, J.S., SCHACHTER, M. & HUGHES, A.D. (1997a). Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells. Br. J. Pharmacol., 121, 1789-1795.
9. CORSINI, A., BONFATTI, M., QUARATO, P., ACCOMAZZO, M.R., RAITERI, M., SARTANI, A., TESTA, R., NICOSIA, S., PAOLETTI, R. & FUMAGALLI, R. (1996). Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol., 28, 687-694.
10. CLUNN, G.F., REFSON, J.S., LYMN, J.S. & HUGHES, A.D. (1997b). Platelet-derived growth factor beta-receptors can both promote and inhibit chemotaxis in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 17, 2622-2629.
11. FAGER, G., HANSSON, G.K., GOWN, A.M., LARSON, D.M., SKALLI, O. & BONDJERS, G. (1989). Human arterial smooth muscle cells in culture: inverse relationship between proliferation and expression of contractile proteins. In vitro Cell. Dev. Biol., 25, 511-520.
12. GAO, T., CHIEN, A.J. & HOSEY, M.M. (1999). Complexes of the alpha1C and beta subunits generate the necessary signal for membrane targeting of class C L-type calcium channels. J. Biol. Chem., 274, 2137-2144.
13. GARCHA, R.S., SEVER, P.S. & HUGHES, A.D. (1993). The action of amlodipine on human subcutaneous resistance arteries studied in vitro. J. Pharmacol. Exp. Ther., 265, 860-865.
14. GOLLASCH, M., HAASE, H., RIED, C., LINDSCHAU, C., MORANO, I., LUFT, F.C. & HALLER, H. (1998). L-type calcium channel expression depends on the differentiated state of vascular smooth muscle cells. FASEB J., 12, 593-601.
15. HERNANDEZ, R.H., ARMAS-HERNANDEZ, M.J., VELASCO, M., ISRAILI, Z.H. & ARMAS- PADILLA, M.C. (2003). Calcium antagonists and atherosclerosis protection in hypertension. Am. J. Ther., 10, 409-414.
16. HUGHES, A.D. (1995). Calcium channels in vascular smooth muscle. J. Vasc. Res., 32, 353-370.
17. IHARA, E., HIRANO, K., HIRANO, M., NISHIMURA, J., NAWATA, H. & KANAIDE, H. (2002). Mechanism of down-regulation of L-type Ca(2+) channel in the proliferating smooth muscle cells of rat aorta. J. Cell Biochem., 87, 242-251.
18. JACKSON, C.L., BUSH, R.C. & BOWYER, D.E. (1989). Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis, 80, 17-26.
19. 2+ currents in rat aortic smooth muscle cells in primary culture. Circ. Res., 79, 14-19.
20. NAKAO, J., ITO, H., OOYAMA, T., CHANG, W.C. & MUROTA, S. (1983). Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14- eicosatetraenoic acid. Effects of A23187, nicardipine and trifluoperazine. Atherosclerosis, 46, 309-319.
21. 3H]dihydropyridine receptors by activation of protein kinase C in chick muscle cells. J. Biol. Chem., 262, 4649-4652.
22. NOMOTO, A., HIROSUMI, J., SEKIGUCHI, C., MUTOH, S., YAMAGUCHI, I. & AOKI, H. (1987). Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery. Atherosclerosis, 64, 255-261.
23. NOMOTO, A., MUTOH, S., HAGIHARA, H. & YAMAGUCHI, I. (1988). Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis, 72, 213-219.
24. OWENS, G.K. (1995). Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev., 75, 487-517.
25. PAOLETTI, R., BERNINI, F., CORSINI, A. & SOMA, M.R. (1995). The antiatherosclerotic effects of calcium antagonists. J. Cardiovasc. Pharmacol., 25 (Suppl 3), S6-S10.
26. PATEL, M.K., MULLOY, B., GALLAGHER, K.L., O'BRIEN, L. & HUGHES, A.D. (2002). The antimitogenic action of the sulphated polysaccharide fucoidan differs from heparin in human vascular smooth muscle cells. Thromb. Haemost., 87, 149-154.
27. PEREZ-GARCIA, M.T., KAMP, T.J. & MARBAN, E. (1995). Functional properties of cardiac L- type calcium channels transiently expressed in HEK293 cells. Roles of alpha 1 and beta subunits. J. Gen. Physiol., 105, 289-305.
28. PETTIT, E.J. & FAY, F.S. (1998). Cytosolic free calcium and the cytoskeleton in the control of leukocyte chemotaxis. Physiol. Rev., 78, 949-967.
29. PITT, B., BYINGTON, R.P., FURBERG, C.D., HUNNINGHAKE, D.B., MANCINI, G.B., MILLER, M.E. & RILEY, W. (2000). Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 102, 1503-1510.
30. QUIGNARD, J.F., FRAPIER, J.M., HARRICANE, M.C., ALBAT, B., NARGEOT, J. & RICHARD, S. (1997). Voltage-gated calcium channel currents in human coronary myocytes. Regulation by cyclic GMP and nitric oxide. J. Clin. Invest., 99, 185-193.
31. RICHARD, S., NEVEU, D., CARNAC, G., BODIN, P., TRAVO, P. & NARGEOT, J. (1992). Differential expression of voltage-gated Ca(2+)-currents in cultivated aortic myocytes. Biochim. Biophys. Acta, 1160, 95-104.
32. ROSS, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809.
33. SCHWARTZ, L.M., McCLESKEY, E.W. & ALMERS, W. (1985). Dihydropyridine receptors in muscle are voltage-dependent but most are not functional calcium channels. Nature, 314, 747-751.
34. SKALLI, O., ROPRAZ, P., TRZECIAK, A., BENZONANA, G., GILLESSEN, D. & GABBIANI, G. (1986). A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell. Biol., 103, 2787-2796.
35. THYBERG, J. (1996). Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int. Rev. Cytol., 169, 183-265.
36. UNLU, S., CLUNN, G., SCHACHTER, M., DEMOLIOU-MASON, C. & HUGHES, A.D. (2001). Action of an HMG CoA reductase inhibitor, lovastatin, on apoptosis of untransformed and ts-SV40 transformed human smooth muscle cells derived from saphenous vein. J. Cardiovasc. Pharmacol., 38, 161-173.
37. ZANCHETTI, A. (2001). The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. Curr. Hypertens. Rep., 3, 350-359.